### ü´† Acute Coronary Syndromes: Reperfusion Failure After Thrombolysis

#### ‚úÖ True Statements
1. **Percutaneous coronary intervention (PCI)** is the preferred reperfusion strategy for patients with **ST-elevation myocardial infarction (STEMI)**.
2. **Thrombolytic therapy** is recommended for patients with **STEMI** if **symptom onset is within 12 hours** and **primary PCI is not available within 120 minutes** of first medical contact.
3. Patients undergoing **thrombolysis** should receive **aspirin**, **intravenous unfractionated heparin**, **enoxaparin**, or **fondaparinux**, and a **300 mg oral clopidogrel loading dose**.
4. **Thrombolytic therapy** is most effective within the **first 3 to 6 hours** after symptom onset.
5. **One quarter to one third of patients** treated with thrombolysis do not achieve successful reperfusion, particularly in the setting of **delayed presentation**.
6. In cases of **failed reperfusion after thrombolysis**, **rescue PCI** is associated with **improved outcomes** compared with conservative management.
7. **Early routine transfer** of patients after thrombolysis facilitates **early rescue PCI** in cases of reperfusion failure or reocclusion.
8. **Repeat thrombolytic therapy** is **not recommended** for failed reperfusion following initial thrombolysis.
9. **Tirofiban**, an intravenous glycoprotein IIb/IIIa inhibitor, is **not indicated** after adequate **P2Y12 inhibitor loading** in patients with failed reperfusion after thrombolysis.
10. **Coronary computed tomography (CT) angiography** should not delay urgent **PCI** in the setting of clear evidence of **failed reperfusion** in STEMI.

#### üí¨ Extra
1. PCI enables mechanical reperfusion and restoration of coronary flow and is associated with lower mortality in STEMI.
2. This time threshold reflects guideline-directed therapy when PCI is not rapidly available.
3. This combination improves vessel patency and outcomes in patients receiving thrombolysis.
4. Delayed administration reduces efficacy and increases likelihood of reperfusion failure.
5. Failure to reperfuse is associated with continued ischemia and infarct expansion.
6. Rescue PCI offers a higher likelihood of reperfusion and reduced infarct size compared to noninvasive options.
7. Transfer protocols aim to minimize time to PCI in the event thrombolysis is unsuccessful.
8. Repeat lytic therapy has not shown consistent benefit and increases bleeding risk.
9. Tirofiban is typically reserved for use in the catheterization lab in selected patients with high thrombus burden.
10. Persistent chest pain and unchanged ST elevation are sufficient indicators of failed reperfusion, warranting immediate intervention.

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Coronary Artery Disease, Acute Coronary Syndromes, Treatment of ST-Elevation Myocardial Infarction, Reperfusion

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **ST-elevation myocardial infarction (STEMI)** is most often caused by **acute thrombotic coronary occlusion** due to plaque rupture or erosion with platelet aggregation.
2. **ST-segment elevation** on electrocardiogram indicates **transmural myocardial ischemia** and necessitates **urgent reperfusion therapy**.
3. **Primary percutaneous coronary intervention (PPCI)** is the preferred reperfusion strategy for **STEMI**, especially at PCI-capable centers or when transfer time is ‚â§120 minutes.
4. The **goal time from first medical contact to PPCI** is **90 minutes or less**.
5. In **hemodynamically stable patients** with **multivessel disease**, **staged PCI of noninfarct artery stenoses** is recommended after successful PCI of the infarct vessel.
6. In selected **hemodynamically stable patients** with **low-complexity multivessel disease**, **noninfarct artery PCI** may be completed at the time of **primary PCI**.
7. **Newer fibrin-specific thrombolytics** (e.g., **alteplase**, **reteplase**, **tenecteplase**) improve infarct artery patency compared to **streptokinase** and are less allergenic.
8. **Intracerebral hemorrhage** occurs in approximately **1% of patients** receiving **fibrin-specific thrombolytic therapy**.
9. **Electrocardiographic evidence of reperfusion** is defined as **‚â•50% resolution of maximal ST-segment elevation** within **60 to 90 minutes** after thrombolysis.
10. After thrombolysis, **all patients** should undergo **coronary angiography prior to discharge**, even if reperfusion appears successful.
11. **Previous intracranial hemorrhage** is an **absolute contraindication** to **thrombolytic therapy** in patients with **ST-elevation myocardial infarction (STEMI)**.
12. **Active bleeding or bleeding diathesis** (excluding menses) is considered an **absolute contraindication** to **thrombolytic therapy in STEMI**.
13. **Intracranial or intraspinal surgery within the past 2 months** is an **absolute contraindication** to **thrombolytic therapy in STEMI**.
14. **Severe uncontrolled hypertension** (unresponsive to emergency therapy) is an **absolute contraindication** to thrombolysis.
15. **Severe uncontrolled hypertension on presentation**, defined as **systolic blood pressure (SBP) >180 mm Hg or diastolic blood pressure (DBP) >110 mm Hg**, is a **relative contraindication** to thrombolytic therapy in STEMI.
16. **Thrombolytic therapy should be administered within 30 minutes of hospital presentation** ("door-to-needle time") in **STEMI patients at non-PCI centers** if **PCI cannot be performed within 120 minutes of first medical contact**.
17. **Electrocardiographic evidence of thrombolysis failure** includes **<50% resolution of ST-segment elevation** at **60‚Äì90 minutes** after thrombolytic administration.
18. In **STEMI patients with successful reperfusion after thrombolysis**, **coronary angiography** should ideally be performed **within 24 hours**, but **not within the first 2 to 3 hours**.
19. **Multivessel revascularization** may be performed **during primary PCI** in selected **hemodynamically stable patients with low-complexity noninfarct artery stenoses**.
20. **Emergency coronary angiography** is indicated in **STEMI patients with persistent chest pain and failed thrombolysis**, regardless of initial hospital capabilities.

#### üí¨ Extra
1. This thrombotic event results in sudden cessation of myocardial perfusion.
2. Prompt reperfusion reduces infarct size and improves clinical outcomes.
3. PPCI is more reliable than thrombolysis in restoring vessel patency.
4. Delays beyond this goal are associated with worse myocardial salvage.
5. Studies have shown lower event rates with complete revascularization strategies.
6. This approach may minimize ischemic burden without delaying PPCI.
7. These agents lyse fibrin-bound clots more efficiently but are more expensive.
8. This bleeding risk is the major limitation of systemic thrombolysis.
9. Serial ECG monitoring helps determine the need for rescue PCI.
10. Angiography allows for detection of residual stenosis or reocclusion.
11. This risk reflects the high likelihood of rebleeding in previously compromised cerebrovascular tissue.
12. Uncontrolled or active bleeding may be worsened by thrombolytic-induced fibrinolysis.
13. Postoperative central nervous system healing remains vulnerable to bleeding risks from systemic thrombolytics.
14. Elevated blood pressure increases the risk of intracerebral hemorrhage with thrombolytic agents.
15. This threshold defines a critical range where bleeding risk may outweigh benefit but is not automatically exclusionary.
16. The 30-minute benchmark represents the system-wide performance goal for thrombolytic therapy initiation.
17. ST resolution monitoring guides the decision to proceed with **rescue PCI**.
18. Early angiography may confound thrombolytic efficacy assessment or increase bleeding risk.
19. This approach improves long-term outcomes and minimizes staged re-intervention in carefully selected patients.
20. Rescue PCI provides mechanical revascularization when pharmacologic reperfusion is inadequate.

#### üî∑ Tags
#Contraindications #DoorToNeedleTime #Hypertension #PCI #MultivesselDisease #Angiography #Cardiology #AcuteCoronarySyndrome #STEMI #PPCI #Thrombolysis #MultivesselPCI #RescuePCI #BleedingRisk #Electrocardiography

#### üìô Reference
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. *JAMA*. 2022;327:662-675. PMID: 35166796 doi:10.1001/jama.2022.0358

#### üÜî Question ID
CVMCQ24008

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures

<!-- Figure: Management of ST-Elevation Myocardial Infarction (STEMI) -->
<figure>
  <img src="Management of ST-Elevation Myocardial Infarction (STEMI).svg" alt="Management of STEMI Algorithm">
  <figcaption>
    <strong>Management of ST-Elevation Myocardial Infarction (STEMI)</strong><br>
    FMC = first medical contact; PCI = percutaneous coronary intervention.<br>
    aIf ‚â•4 hours have elapsed since symptom onset, PCI is preferred.<br>
    bHigh-risk features, such as cardiogenic shock and heart failure, favor PCI.<br>
    cFMC-to-device (‚Äúdoor-to-balloon‚Äù) goal for patients being transferred for primary PCI is as soon as possible and ‚â§120 minutes.<br>
    dP2Y12 inhibitors: clopidogrel, prasugrel, ticagrelor.<br>
    ePatients with STEMI presenting to a hospital without PCI capabilities and who cannot be transferred to a PCI-capable center and undergo PCI within 120 minutes of FMC (‚Äúdoor-to-balloon time‚Äù) should be treated with thrombolytic therapy within 30 minutes of hospital presentation (‚Äúdoor-to-needle time‚Äù) as a systems goal unless thrombolytic therapy is contraindicated. It is reasonable to transfer patients treated with thrombolytic therapy to a PCI-capable center for subsequent coronary angiography. Angiography should not be performed within 2 to 3 hours after successful thrombolytic therapy but is ideally performed within 24 hours. Emergent coronary angiography is indicated for patients with clinical thrombolysis failure, including patients with persistent chest pain and/or &lt;50% resolution of baseline ST-segment elevation at 60-90 minutes following thrombolytic administration.<br>
    fIn patients with successful reperfusion after thrombolytic therapy, it is reasonable to transfer these patients to a PCI-capable center for subsequent coronary angiography. Angiography should not be performed within 2 to 3 hours after thrombolytic therapy administration but is ideally performed within 24 hours.<br>
    Source: Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. <em>Circulation</em>. 2022;145:e18-e114. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34882435" target="_blank">34882435</a> doi: <a href="https://doi.org/10.1161/CIR.0000000000001038" target="_blank">10.1161/CIR.0000000000001038</a>
  </figcaption>
</figure>

<!-- Figure: Contraindications for Thrombolytic Therapy -->
<table>
  <caption><strong>Contraindications and Cautions for Thrombolytic Therapy in ST-Elevation Myocardial Infarction</strong></caption>
  <thead>
    <tr><th colspan="1">Absolute Contraindications</th></tr>
  </thead>
  <tbody>
    <tr><td>Any previous intracranial hemorrhage</td></tr>
    <tr><td>Known structural cerebrovascular lesion (e.g., arteriovenous malformation)</td></tr>
    <tr><td>Known malignant intracranial neoplasm (primary or metastatic)</td></tr>
    <tr><td>Ischemic stroke within 3 mo (except acute ischemic stroke within 4.5 h)</td></tr>
    <tr><td>Suspected aortic dissection</td></tr>
    <tr><td>Active bleeding or bleeding diathesis (excluding menses)</td></tr>
    <tr><td>Significant closed head or facial trauma within 3 mo</td></tr>
    <tr><td>Intracranial or intraspinal surgery within 2 mo</td></tr>
    <tr><td>Severe uncontrolled hypertension (unresponsive to emergency therapy)</td></tr>
    <tr><td>For streptokinase: treatment within the previous 6 mo</td></tr>
  </tbody>
  <thead>
    <tr><th colspan="1">Relative Contraindications</th></tr>
  </thead>
  <tbody>
    <tr><td>History of chronic, severe, poorly controlled hypertension</td></tr>
    <tr><td>Severe uncontrolled hypertension on presentation (SBP &gt;180 mm Hg or DBP &gt;110 mm Hg)<sup>a</sup></td></tr>
    <tr><td>History of ischemic stroke (&gt;3 mo previously)</td></tr>
    <tr><td>Dementia</td></tr>
    <tr><td>Known intracranial abnormality not covered in absolute contraindication</td></tr>
    <tr><td>Traumatic or prolonged (&gt;10 min) CPR</td></tr>
    <tr><td>Major surgery within 3 wk</td></tr>
    <tr><td>Recent (within 2‚Äì4 wk) internal bleeding</td></tr>
    <tr><td>Noncompressible vascular puncture site</td></tr>
    <tr><td>Pregnancy</td></tr>
    <tr><td>Active peptic ulcer disease</td></tr>
    <tr><td>Oral anticoagulant therapy</td></tr>
  </tbody>
</table>

<p><em>CPR = cardiopulmonary resuscitation; DBP = diastolic blood pressure; SBP = systolic blood pressure.<br>
<sup>a</sup>Viewed as advisory for clinical decision making and may not be all-inclusive or definitive.</em></p>

<p><em>Reprinted from O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <strong>J Am Coll Cardiol</strong>. 2013;61:e78‚Äìe140. 
<a href="https://pubmed.ncbi.nlm.nih.gov/23256914" target="_blank">PMID: 23256914</a> 
doi: <a href="https://doi.org/10.1016/j.jacc.2012.11.019" target="_blank">10.1016/j.jacc.2012.11.019</a>. 
¬©2013, with permission from American College of Cardiology Foundation and the American Heart Association, Inc.</em></p>
